Study to Evaluate the Safety of Nanoxel M Inj.

Samyang Biopharmaceuticals Corporation

Status: Enrolling

Conditions: Breast Cancer; Esophageal Cancer; Gastric Cancer; Non-small Cell Lung Cancer; Head and Neck Cancer; Ovarian Cancer; Prostate Cancer

Study type: Observational

Funder types: Industry

Identifiers

NCT04066335

DPM401

Details and patient eligibility

About

Study to evaluate the safety of Nanoxel M inj. administration in patients.

Full description

This is a multi-center, prospective observational study to observe the incidence of adverse events under actual clinical settings to test the safety of Nanoxel-M inj. administration in patients with breast cancer, non-small cell lung cancer, prostate cancer, ovarian cancer, head & neck cancer, gastric cancer or esophageal cancer.

Enrollment: 1,498 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Adults ≥18 years old
2. Patients who have signed written consent form prior to participating in the clinical trial
3. Patients who are assessed as adequate to administer Nanoxel M injection.

Exclusion criteria

1. Patients who have shown severe hypersensitivity to Docetaxel and concomitant drugs